Literature DB >> 29242724

Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease.

Changhwan Sung1, Jai Hyuen Lee2, Jungsu S Oh1, Minyoung Oh1, Sang Ju Lee1, Seung Jun Oh1, Sun Ju Chung3, Chong Sik Lee3, Jae Seung Kim1.   

Abstract

PURPOSE: Dopamine transporter imaging is suggested to be a useful imaging biomarker for Parkinson's disease (PD) progression and monitoring drug effects. We investigated the longitudinal decline characteristics of striatal [18F]FP-CIT uptake in PD.
METHODS: We retrospectively reviewed 35 PD patients and 9 non-PD patients. All patients underwent [18F]FP-CIT PET at the initial diagnosis and follow-up. PET images were spatially normalized and analyzed with eight striatal and one occipital VOI templates. We measured the specific to non-specific binding ratio (SNBR) of the striatal subregions and calculated the absolute annual reduction (AAR) and relative annual reduction (%RAR) of the SNBRs.
RESULTS: Total striatal SNBRs in PD patients were significantly lower than those in non-PD patients, with the most significant difference in the posterior putamen. Both AAR (0.26 ± 0.14 vs. 0.09 ± 0.19, p < 0.05) and %RAR (6.9 ± 3.5 vs. 1.2 ± 2.7, p < 0.001) of total striatal SNBRs were significantly greater in PD than non-PD patients. There were no significant differences in the AAR and %RAR of total striatal SNBRs between elderly and young onset PD. The AARs of the posterior putamen were higher in early PD than in advanced PD. Conversely, the %RARs were not significantly different between early and more advanced PD. The disease duration was significantly negatively correlated with the AAR but not with the %RAR of the posterior putamen.
CONCLUSIONS: The longitudinal decline of striatal [18F]FP-CIT uptake in PD was nonlinear and significantly faster than that in non-PD, with a different rate of decline among the striatal subregions.

Entities:  

Keywords:  Dopamine transporter imaging; Longitudinal decline; Parkinson’s disease; [18F]FP-CIT pet

Year:  2017        PMID: 29242724      PMCID: PMC5721089          DOI: 10.1007/s13139-017-0481-x

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  29 in total

1.  [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Authors:  K Marek; R Innis; C van Dyck; B Fussell; M Early; S Eberly; D Oakes; J Seibyl
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

2.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

3.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

Authors:  S J Kish; K Shannak; O Hornykiewicz
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

4.  [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease.

Authors:  A Winogrodzka; P Bergmans; J Booij; E A van Royen; A G Janssen; E C Wolters
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

5.  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

Authors: 
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

6.  Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT.

Authors:  W Staffen; A Mair; J Unterrainer; E Trinka; G Ladurner
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

7.  Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.

Authors:  E Nurmi; J Bergman; O Eskola; O Solin; S M Hinkka; P Sonninen; J O Rinne
Journal:  J Cereb Blood Flow Metab       Date:  2000-11       Impact factor: 6.200

8.  Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.

Authors:  Minyoung Oh; Jae Seung Kim; Ji Young Kim; Kwang-Ho Shin; Seol Hoon Park; Hye Ok Kim; Dae Hyuk Moon; Seung Jun Oh; Sun Ju Chung; Chong Sik Lee
Journal:  J Nucl Med       Date:  2012-02-09       Impact factor: 10.057

9.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.

Authors:  F J Vingerhoets; B J Snow; C S Lee; M Schulzer; E Mak; D B Calne
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

10.  Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [(18)F]FP-CIT PET/CT.

Authors:  Eunkyung Park; Yu Mi Hwang; Chan-Nyoung Lee; Sujin Kim; Sun Young Oh; Young Chul Kim; Jae Gol Choe; Kun Woo Park
Journal:  Nucl Med Mol Imaging       Date:  2013-12-11
View more
  5 in total

Review 1.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

2.  Alterations of Striatal Subregions in a Prion Protein Gene V180I Mutation Carrier Presented as Frontotemporal Dementia With Parkinsonism.

Authors:  Zhongyun Chen; Jinghong Ma; Li Liu; Shuying Liu; Jing Zhang; Min Chu; Zhen Wang; Piu Chan; Liyong Wu
Journal:  Front Aging Neurosci       Date:  2022-04-15       Impact factor: 5.702

3.  Treatment Enhances Betweenness Centrality of Fronto-Parietal Network in Parkinson's Patients.

Authors:  Qing Liu; ZhongYan Shi; Kexin Wang; Tiantian Liu; Shintaro Funahashi; Jinglong Wu; Jian Zhang
Journal:  Front Comput Neurosci       Date:  2022-05-26       Impact factor: 3.387

4.  Clinical factors and dopamine transporter availability for the prediction of outcomes after globus pallidus deep brain stimulation in Parkinson's disease.

Authors:  Seung Hyun Lee; Mina Kim; Jooyoung Lee; Jae-Woo Kim; Mi Sun Kim; Sungyang Jo; Sang Ryong Jeon; Sun Ju Chung
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

5.  Imaging of dopamine transporters in Parkinson disease: a meta-analysis of 18 F/123 I-FP-CIT studies.

Authors:  Yanyan Kong; Chencheng Zhang; Kawai Liu; Aparna Wagle Shukla; Bomin Sun; Yihui Guan
Journal:  Ann Clin Transl Neurol       Date:  2020-08-14       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.